ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 132 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,700,980 | -28.9% | 683,000 | 0.0% | 0.00% | -25.0% |
| Q2 2023 | $19,267,430 | +64.0% | 683,000 | 0.0% | 0.00% | +100.0% |
| Q1 2023 | $11,747,600 | -14.6% | 683,000 | 0.0% | 0.00% | -33.3% |
| Q4 2022 | $13,755,620 | -7.0% | 683,000 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $14,794,000 | -22.9% | 683,000 | 0.0% | 0.00% | -25.0% |
| Q2 2022 | $19,192,000 | -39.1% | 683,000 | 0.0% | 0.00% | -20.0% |
| Q1 2022 | $31,514,000 | -45.1% | 683,000 | 0.0% | 0.01% | -44.4% |
| Q4 2021 | $57,413,000 | +26.1% | 683,000 | 0.0% | 0.01% | +12.5% |
| Q3 2021 | $45,515,000 | +27.7% | 683,000 | +1.9% | 0.01% | +33.3% |
| Q2 2021 | $35,644,000 | +122.0% | 670,000 | +81.1% | 0.01% | +100.0% |
| Q1 2021 | $16,054,000 | -63.6% | 370,000 | -56.5% | 0.00% | -66.7% |
| Q4 2020 | $44,149,000 | +103.4% | 850,000 | +28.0% | 0.01% | +80.0% |
| Q3 2020 | $21,706,000 | +0.4% | 664,000 | +47.6% | 0.01% | 0.0% |
| Q2 2020 | $21,609,000 | – | 450,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |